We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
LYNKUET (Bayer Australia Ltd)
Product name
LYNKUET
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
179 (255 working days)
Active ingredients
elinzanetant
Registration type
NCE/ NBE
Indication
The approved indication for this therapeutic good is:
- LYNKUET is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause (see Section 5.1 Pharmacodynamic properties – Clinical Trials).